期刊
CELL STEM CELL
卷 4, 期 4, 页码 289-300出版社
CELL PRESS
DOI: 10.1016/j.stem.2009.03.010
关键词
-
资金
- The Starr Foundation [U01 HL66952, U01 NS047458]
- The Malcolm Hewitt Wiener Foundation
The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据